Clinical Pharmacokinetics and Pharmacodynamics of Repaglinide
- 1 January 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 41 (7), 471-483
- https://doi.org/10.2165/00003088-200241070-00002
Abstract
Repaglinide is a novel, fast-acting prandial oral hypoglycaemic agent developed for the treatment of patients with type 2 diabetes whose disease cannot be controlled by diet and exercise alone. Although repaglinide binds to the sulphonylurea binding sites on pancreatic β-cells and has a similar mechanism of action, repaglinide exhibits distinct pharmacological properties compared with these agents. Following administration, repaglinide is absorbed rapidly and has a fast onset of dose-dependent blood-glucose lowering effect. The drug is eliminated rapidly via the biliary route, without accumulation in the plasma after multiple doses. Repaglinide is well tolerated in patients with type 2 diabetes, including elderly patients and patients with hepatic or renal impairment. The pharmacokinetic profile of repaglinide and the improvements in post-prandial hyperglycaemia and overall glycaemic control make repaglinide suitable for administration preprandially, with the opportunity for flexible meal arrangements, including skipped meals, without the risk of hypoglycaemia.Keywords
This publication has 35 references indexed in Scilit:
- Meglitinide Analogues in the Treatment of Type 2 Diabetes MellitusDrugs & Aging, 2000
- Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.Diabetes Care, 2000
- Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver DiseaseThe Journal of Clinical Pharmacology, 2000
- The Human Hepatic Cytochromes P450 Involved in Drug MetabolismCritical Reviews in Toxicology, 1992
- Oral Hypoglycemic AgentsNew England Journal of Medicine, 1989
- Protein Binding Drug Displacement InteractionsClinical Pharmacokinetics, 1989
- Sulphonylurea Antidiabetic DrugsDrugs, 1989
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Protein Binding and Drug ClearanceClinical Pharmacokinetics, 1984
- Clinical Pharmacokinetics of DigoxinClinical Pharmacokinetics, 1977